Given numerous studies demonstrating the importance of aberrant DOT1L function in the pathogenesis of MLL-rearranged ALL[33,34] and genetic studies demonstrating a dependency on DOT1L in these leukemias[40], more recent attention has focused on the development and preclinical validation of DOT1L inhibitors. The gene discussed is KMT2A; the disease is leukemia.